A new study shows successful immunotherapy of a detrimental gastrointestinal disease using the complement inhibitor eculizumab.
References
Ozen, A. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-00830-z (2021).
Ozen, A. et al. N. Engl. J. Med. 377, 52–61 (2017).
Kurolap, A. et al. N. Engl. J. Med. 377, 87–89 (2017).
Lintner, K. E. et al. Front. Immunol. 7, 36 (2016).
Barnum, S. & Schein, T. (eds.) The Complement FactsBook 2nd edn (Academic Press, 2018).
Lublin, D. M. & Atkinson, J. P. Annu. Rev. Immunol. 7, 35–58 (1989).
Dho, S. H., Lim, J. C. & Kim, L. K. Immune Netw. 18, e11 (2018).
Lachmann, P. J. Immunol. Today 12, 312–315 (1991).
Ekdahl, K. N. et al. Immunol. Rev. 274, 245–269 (2016).
Savelli, S. L. et al. Front. Immunol. 10, 885 (2019).
Mulvihill, E. et al. Lupus Sci. Med. 6, e000333 (2019).
Kamitaki, N. et al. Nature 582, 577–581 (2020).
Acknowledgements
The authors are supported by a National Institute of Arthritis Musculoskeletal and Skin Disease grant (R01 AR073311) from the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Yu, CY., Ardoin, S.P. Complement inhibitor for therapy of CHAPLE. Nat Immunol 22, 106–108 (2021). https://doi.org/10.1038/s41590-020-00842-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-020-00842-9
- Springer Nature America, Inc.